Fluidigm Corporation  

(Public, NASDAQ:FLDM)   Watch this stock  
Find more results for Gene Smith´┐Ż
24.74
+0.43 (1.77%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.00 - 25.05
52 week 21.71 - 46.38
Open 24.32
Vol / Avg. 0.00/445,236.00
Mkt cap 714.78M
P/E     -
Div/yield     -
EPS -1.89
Shares 28.78M
Beta 1.01
Inst. own 107%
Jul 29, 2015
Q2 2015 Fluidigm Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 7, 2015
Q1 2015 Fluidigm Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 Fluidigm Corp Earnings Release
Mar 3, 2015
Fluidigm Corp at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -59.60% -45.36%
Operating margin -52.38% -44.51%
EBITD margin - -26.91%
Return on average assets -15.92% -20.15%
Return on average equity -43.64% -42.81%
Employees 474 -
CDP Score - -

Address

7000 Shoreline Ct Ste 100
SOUTH SAN FRANCISCO, CA 94080-7603
United States - Map
+1-650-2666000 (Phone)
+1-650-8717152 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Fluidigm Corp develops, manufactures, and markets microfluidic systems. The Company provides its products to academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies in markets, such as single-cell genomics, applied genotyping, and sample preparation. The Company’s microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. The Company markets four microfluidic systems, including 18 different commercial IFCs, and three families of assay chemistries. The Company’s BioMark HD System performs gene expression analysis, single-cell targeted gene expression analysis, SNP genotyping and digital PCR. C1 Single-Cell Auto Prep System enables isolation, processing, and profiling of individual cells for genomic analysis. The EP1 System performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, and end-point digital PCR.

Officers and directors

Samuel D. Colella MBA Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Gajus Vincent Worthington President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Vikram Jog Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Fredric T. Walde Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
William Maxwell Smith J.D. Executive Vice President - Legal Affairs, General Counsel, Secretary
Age: 63
Bio & Compensation  - Reuters
Robert C. Jones Executive Vice President - Research and Development
Age: 60
Bio & Compensation  - Reuters
Mai Chan Yow Executive Vice President - Worldwide Manufacturing and Managing Director of Fluidigm Singapore Pte. Ltd.
Age: 56
Bio & Compensation  - Reuters
Gerhard F. Burbach Independent Director
Age: 52
Bio & Compensation  - Reuters
Evan Jones Independent Director
Age: 57
Bio & Compensation  - Reuters
Patrick Schwager Jones Independent Director
Age: 70
Bio & Compensation  - Reuters